Ascentage Pharma Presents Alrizomadlin Data at ASCO Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Ascentage Pharma announced that the Company presented its first dataset of alrizomadlin, an MDM2-p53 inhibitor from the Company's apoptosis-targeted pipeline, as monotherapy or in combination with lisaftoclax in pediatric patients with relapsed/metastatic rhabdomyosarcoma or other soft-tissue sarcomas, in a rapid oral presentation at the 62nd American Society of Clinical Oncology, ASCO, Annual Meeting. Key Highlights: In the monotherapy arm, 1 patient with refractory RMS achieved CR. In the combination arm, among 17 response-evaluable pediatric patients with relapsed/refractory solid tumors, the ORR was 23.5%, including 1 CR in a patient with EWS, as well as PRs in 2 patients with RMS and 1 patient with NB. The disease control rate was 70.6%. The regimen demonstrated a manageable safety profile and preliminary antitumor activity in pediatric solid tumors, supporting further investigation
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AAPG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AAPG
Wall Street analysts forecast AAPG stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.090
Low
45.00
Averages
48.67
High
51.00
Current: 17.090
Low
45.00
Averages
48.67
High
51.00
About AAPG
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ascentage Pharma Showcases Key Clinical Data at EHA2026
- Core Asset Updates: Ascentage Pharma presented 17 clinical updates at EHA2026, including 8 poster presentations, showcasing the latest research progress of its core assets, olverembatinib and lisaftoclax, highlighting the company's global innovation capabilities in hematologic malignancies.
- CML Efficacy: Olverembatinib demonstrated a complete cytogenetic response rate of 76.2% in chronic-phase CML patients, showing deep and durable clinical responses in multi-line TKI-resistant patients, further solidifying its potential as a second-line treatment option.
- ALL Prospects: In newly diagnosed Ph+ ALL patients, the combination of olverembatinib with low-intensity chemotherapy achieved a clinical response rate of 94.4%, indicating its significant application value in frontline therapy.
- Pediatric Study: In pediatric patients with relapsed/refractory Ph+ ALL, the combination of olverembatinib and lisaftoclax showed an overall response rate of 88.9%, suggesting that this chemotherapy-free regimen may provide new treatment options for this population.
See More
Ascentage Pharma Presents New Therapy at ASCO Meeting
- Clinical Trial Results: At the 2026 ASCO Annual Meeting, Ascentage Pharma presented data showing that the combination of olverembatinib and blinatumomab achieved a 91% complete response rate in patients with chronic myeloid leukemia (CML-LBP) and Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL), highlighting the significant efficacy of this treatment regimen.
- Safety Assessment: The combination therapy demonstrated a favorable safety profile, with most adverse events classified as grade 1-2, consistent with the known toxicities of each agent, indicating its feasibility and tolerability in clinical applications, potentially offering new treatment options for difficult-to-treat patients.
- Global Registrational Studies: Ascentage Pharma is conducting three global registrational Phase III trials to evaluate olverembatinib across multiple indications, including newly diagnosed Ph+ ALL and SDH-deficient gastrointestinal stromal tumors (GIST), which will further enhance its positioning in the international market.
- Strategic Partnership Agreement: Ascentage Pharma signed an exclusive option agreement with Takeda, granting Takeda the global rights to develop and commercialize olverembatinib outside of mainland China, Hong Kong, Macau, and Taiwan, which could provide significant market expansion opportunities for the company.
See More
Ascentage Pharma Presents Six Clinical Studies at ASCO Annual Meeting
- Clinical Research Showcase: Ascentage Pharma presents six clinical study abstracts at the 2026 ASCO Annual Meeting, with three selected for rapid oral presentations and three for poster sessions, highlighting the company's ongoing innovation in cancer treatment.
- Combination Therapy: In a multicenter Phase Ib study, olverembatinib combined with blinatumomab showed promising results in chronic myeloid leukemia patients, with four out of five patients achieving complete remission, indicating the potential and safety of this combination therapy.
- Pediatric Oncology Study: Research on relapsed rhabdomyosarcoma demonstrated that the combination of alrizomadlin and lisaftoclax resulted in a 30% objective response rate and an 80% disease control rate, offering new hope for pediatric cancer treatment.
- Global Clinical Trials: Ascentage Pharma is conducting the global POLARIS-2 Phase III trial to evaluate olverembatinib's efficacy in chronic-phase chronic myeloid leukemia patients, which is expected to provide critical data for the drug's registration.
See More
Ascentage Pharma Showcases 17 Clinical Advances at EHA2026
- Clinical Advances Showcase: Ascentage Pharma will present 17 clinical advances of its core assets at the 2026 European Hematology Association Congress, including 8 poster presentations, demonstrating the company's research strength and market influence in the hematology field.
- Innovative Therapies Highlighted: The conference will focus on Olverembatinib and Lisaftoclax, with the former being China's first approved third-generation BCR-ABL inhibitor and the latter the first China-developed Bcl-2 selective inhibitor, marking significant breakthroughs in cancer treatment.
- Global Academic Exchange: The EHA Congress gathers hematology professionals worldwide, providing a platform for sharing the latest research and clinical data, and Ascentage's participation will enhance its visibility and influence in the international academic community.
- Future Growth Potential: By showcasing these clinical data, Ascentage Pharma not only attracts potential investors but also lays the groundwork for future FDA registration applications and market promotions, thereby strengthening its competitiveness in the global market.
See More
Key Wall Street Rating Changes Overview
- Intel Upgrade: Evercore ISI upgraded Intel from 'In Line' to 'Outperform', citing improved execution under the new CEO, who has fixed the balance sheet and put the company back on a competitive track, which is expected to drive stock price appreciation.
- Maxlinear Upgrade: Needham upgraded Maxlinear from 'Hold' to 'Buy' after the company reported a Q1 beat and guided Q2 well above Street expectations, indicating strong demand driven by data center growth, which could enhance future revenue.
- Shake Shack Initiation: Guggenheim initiated coverage on Shake Shack with a 'Buy' rating and a $120 price target, anticipating profit growth for the burger chain, reflecting positive market sentiment regarding its future performance.
- Oracle Initiation: Wedbush initiated coverage on Oracle with an 'Outperform' rating and a $225 price target, arguing that the market is fundamentally misinterpreting the company's aggressive investment cycle as speculative risk, which could lead to stock price increases.
See More
Ascentage Pharma Showcases Six Clinical Studies at ASCO Annual Meeting
- Clinical Study Showcase: Ascentage Pharma presents six clinical study abstracts at the 2026 ASCO Annual Meeting, including three rapid oral presentations and three poster presentations, highlighting its innovative capabilities and clinical value in cancer treatment.
- Drug Candidate Highlights: The showcased drugs include Olverembatinib, the first approved third-generation BCR-ABL inhibitor in China; Lisaftoclax, the first China-developed Bcl-2 selective inhibitor; and Alrizomadlin, an MDM2-p53 inhibitor, demonstrating the company's leadership in oncology.
- Global Recognition: The Chief Medical Officer noted that this marks the ninth consecutive year of presentations at ASCO, reflecting global scientific community recognition of the clinical value of its drug candidates, further advancing its global clinical development agenda.
- Future Development Plans: The company is conducting FDA-cleared global registrational Phase III trials aimed at accelerating the drug approval process to meet urgent patient needs for new treatment options, showcasing its strategic positioning in the global market.
See More
Ascentage Pharma Showcases Key Clinical Data at EHA2026
- Core Asset Updates: Ascentage Pharma presented 17 clinical updates at EHA2026, including 8 poster presentations, showcasing the latest research progress of its core assets, olverembatinib and lisaftoclax, highlighting the company's global innovation capabilities in hematologic malignancies.
- CML Efficacy: Olverembatinib demonstrated a complete cytogenetic response rate of 76.2% in chronic-phase CML patients, showing deep and durable clinical responses in multi-line TKI-resistant patients, further solidifying its potential as a second-line treatment option.
- ALL Prospects: In newly diagnosed Ph+ ALL patients, the combination of olverembatinib with low-intensity chemotherapy achieved a clinical response rate of 94.4%, indicating its significant application value in frontline therapy.
- Pediatric Study: In pediatric patients with relapsed/refractory Ph+ ALL, the combination of olverembatinib and lisaftoclax showed an overall response rate of 88.9%, suggesting that this chemotherapy-free regimen may provide new treatment options for this population.
See More
Ascentage Pharma Presents New Therapy at ASCO Meeting
- Clinical Trial Results: At the 2026 ASCO Annual Meeting, Ascentage Pharma presented data showing that the combination of olverembatinib and blinatumomab achieved a 91% complete response rate in patients with chronic myeloid leukemia (CML-LBP) and Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL), highlighting the significant efficacy of this treatment regimen.
- Safety Assessment: The combination therapy demonstrated a favorable safety profile, with most adverse events classified as grade 1-2, consistent with the known toxicities of each agent, indicating its feasibility and tolerability in clinical applications, potentially offering new treatment options for difficult-to-treat patients.
- Global Registrational Studies: Ascentage Pharma is conducting three global registrational Phase III trials to evaluate olverembatinib across multiple indications, including newly diagnosed Ph+ ALL and SDH-deficient gastrointestinal stromal tumors (GIST), which will further enhance its positioning in the international market.
- Strategic Partnership Agreement: Ascentage Pharma signed an exclusive option agreement with Takeda, granting Takeda the global rights to develop and commercialize olverembatinib outside of mainland China, Hong Kong, Macau, and Taiwan, which could provide significant market expansion opportunities for the company.
See More
Ascentage Pharma Presents Six Clinical Studies at ASCO Annual Meeting
- Clinical Research Showcase: Ascentage Pharma presents six clinical study abstracts at the 2026 ASCO Annual Meeting, with three selected for rapid oral presentations and three for poster sessions, highlighting the company's ongoing innovation in cancer treatment.
- Combination Therapy: In a multicenter Phase Ib study, olverembatinib combined with blinatumomab showed promising results in chronic myeloid leukemia patients, with four out of five patients achieving complete remission, indicating the potential and safety of this combination therapy.
- Pediatric Oncology Study: Research on relapsed rhabdomyosarcoma demonstrated that the combination of alrizomadlin and lisaftoclax resulted in a 30% objective response rate and an 80% disease control rate, offering new hope for pediatric cancer treatment.
- Global Clinical Trials: Ascentage Pharma is conducting the global POLARIS-2 Phase III trial to evaluate olverembatinib's efficacy in chronic-phase chronic myeloid leukemia patients, which is expected to provide critical data for the drug's registration.
See More
Ascentage Pharma Showcases 17 Clinical Advances at EHA2026
- Clinical Advances Showcase: Ascentage Pharma will present 17 clinical advances of its core assets at the 2026 European Hematology Association Congress, including 8 poster presentations, demonstrating the company's research strength and market influence in the hematology field.
- Innovative Therapies Highlighted: The conference will focus on Olverembatinib and Lisaftoclax, with the former being China's first approved third-generation BCR-ABL inhibitor and the latter the first China-developed Bcl-2 selective inhibitor, marking significant breakthroughs in cancer treatment.
- Global Academic Exchange: The EHA Congress gathers hematology professionals worldwide, providing a platform for sharing the latest research and clinical data, and Ascentage's participation will enhance its visibility and influence in the international academic community.
- Future Growth Potential: By showcasing these clinical data, Ascentage Pharma not only attracts potential investors but also lays the groundwork for future FDA registration applications and market promotions, thereby strengthening its competitiveness in the global market.
See More
Key Wall Street Rating Changes Overview
- Intel Upgrade: Evercore ISI upgraded Intel from 'In Line' to 'Outperform', citing improved execution under the new CEO, who has fixed the balance sheet and put the company back on a competitive track, which is expected to drive stock price appreciation.
- Maxlinear Upgrade: Needham upgraded Maxlinear from 'Hold' to 'Buy' after the company reported a Q1 beat and guided Q2 well above Street expectations, indicating strong demand driven by data center growth, which could enhance future revenue.
- Shake Shack Initiation: Guggenheim initiated coverage on Shake Shack with a 'Buy' rating and a $120 price target, anticipating profit growth for the burger chain, reflecting positive market sentiment regarding its future performance.
- Oracle Initiation: Wedbush initiated coverage on Oracle with an 'Outperform' rating and a $225 price target, arguing that the market is fundamentally misinterpreting the company's aggressive investment cycle as speculative risk, which could lead to stock price increases.
See More
Ascentage Pharma Showcases Six Clinical Studies at ASCO Annual Meeting
- Clinical Study Showcase: Ascentage Pharma presents six clinical study abstracts at the 2026 ASCO Annual Meeting, including three rapid oral presentations and three poster presentations, highlighting its innovative capabilities and clinical value in cancer treatment.
- Drug Candidate Highlights: The showcased drugs include Olverembatinib, the first approved third-generation BCR-ABL inhibitor in China; Lisaftoclax, the first China-developed Bcl-2 selective inhibitor; and Alrizomadlin, an MDM2-p53 inhibitor, demonstrating the company's leadership in oncology.
- Global Recognition: The Chief Medical Officer noted that this marks the ninth consecutive year of presentations at ASCO, reflecting global scientific community recognition of the clinical value of its drug candidates, further advancing its global clinical development agenda.
- Future Development Plans: The company is conducting FDA-cleared global registrational Phase III trials aimed at accelerating the drug approval process to meet urgent patient needs for new treatment options, showcasing its strategic positioning in the global market.
See More
